RNA therapy: the next big thing after monoclonal antibodies?

Introduction

RNA therapies have been in development for a number of years, but are yet to achieve any notable commercial success. Improvements have been made following initial attempts and the technology may finally be coming to fruition.

Scope

*Strategic review of the different RNA therapy technology offerings

*Assessment of the commercial potential of key products

*Analysis of the RNA therapy pipeline according to key metrics

*Guidance on the factors that dictate RNA therapy design and the markets best suited to offer returns

Highlights

With the loss of patent protection on maturing blockbusters, innovative new products are required if the pharmaceutical industry is to maintain sales. RNA therapy potentially provides a rich source of such products, allowing targets that are not 'druggable' by other technologies to be exploited.

Despite a number of attempts, only one RNA therapy has reached the market. However, new mechanisms such as RNA interference have given rise to a generation of pipeline candidates characterized by improved safety and efficacy.

While sales on the scale of those enjoyed by monoclonal antibodies seem a way off, evidence suggests RNA therapy is now on course to deliver commercial returns.

Reasons to Purchase

*Assess the 134 RNA therapies in preclinical development and beyond

*Understand how RNA therapies fit alongside small molecule drugs, therapeutic proteins and monoclonal antibodies

*Understand reasons for the lack of approvals to date and how to maximize chances of commercial success